| Amp-Future Biotech Co., Ltd. Amp-Future Biotech specializes in the development, production, and sales of isothermal nucleic acid amplification reagents. Our proprietary MIRA technology (Multienzyme Isothermal Rapid Amplification) ensures fast, accurate, and portable molecular detection, suitable for on-site testing in diverse fields including clinical, agriculture, veterinary , food safety and genetic technologies.
|
Core Technology
| MIRA technology Multienzyme lsothermal Rapid Amplification(MIRA)is a multi-enzyme isothermal nucleic acid rapid amplification technology, relying on the synergy of multiple functional proteins at room temperature to achieve rapid nucleic acid amplification. MIRA represents the future of molecular detection. Developed over 10 years of technical expertise, MIRA is the core platform behind a range of products including Rapid Nucleic Acid Release Technology, Self-testing Nucleic Acid Detection Device, and other advanced detection instruments. Our future innovations include Microfluidic Technology and Automated Detection Systems , offering high sensitivity, rapid results, and low contamination risk-perfect for POCT situations.
|
Under room temperature ● With the assistance of auxiliary proteins and single-strand binding proteins, the recombinase and primers form a complex. ● Search the homologous sequence and combine the target homology domain, forming a D-loop at the homologous site and strand exchange begins. ● With the recombinase dissociate from the complex, the polymerase also binds to the 3'end of the primer, then started the chain extension.
| 
|
| R&D and productionAmp-future has become the key supplier of several leading company in the diagnostic industry. We has obtained certifications such as NMPA, CE, and the Veterinary Drug Registration License etc. The company is equipped with advanced facilities and operates a Class 100,000 cleanroom environment. All core raw materials are independently manufactured, ensuring complete control over product quality. With an annual reagent production capacity exceeding 90 million tests, our business footprint covers the entire domestic market and extends across Europe, North America, Middle East and Asia.
|
https://www.linkedin.com/company/amp-future-bio/posts/?feedView=all
https://www.amp-futurebio.com/
|
Amp-Future Biotech Co., Ltd.
Amp-Future Biotech specializes in the development, production, and sales of isothermal nucleic acid amplification reagents. Our proprietary MIRA technology (Multienzyme Isothermal Rapid Amplification) ensures fast, accurate, and portable molecular detection, suitable for on-site testing in diverse fields including clinical, agriculture, veterinary , food safety and genetic technologies.
Core Technology
MIRA technology
Multienzyme lsothermal Rapid Amplification(MIRA)is a multi-enzyme isothermal nucleic acid rapid amplification technology, relying on the synergy of multiple functional proteins at room temperature to achieve rapid nucleic acid amplification.
MIRA represents the future of molecular detection. Developed over 10 years of technical expertise, MIRA is the core platform behind a range of products including Rapid Nucleic Acid Release Technology, Self-testing Nucleic Acid Detection Device, and other advanced detection instruments. Our future innovations include Microfluidic Technology and Automated Detection Systems , offering high sensitivity, rapid results, and low contamination risk-perfect for POCT situations.
Under room temperature
● With the assistance of auxiliary proteins and single-strand binding proteins, the recombinase and primers form a complex.
● Search the homologous sequence and combine the target homology domain, forming a D-loop at the homologous site and strand exchange begins.
● With the recombinase dissociate from the complex, the polymerase also binds to the 3'end of the primer, then started the chain extension.
R&D and production
Amp-future has become the key supplier of several leading company in the diagnostic industry. We has obtained certifications such as NMPA, CE, and the Veterinary Drug Registration License etc.
The company is equipped with advanced facilities and operates a Class 100,000 cleanroom environment. All core raw materials are independently manufactured, ensuring complete control over product quality. With an annual reagent production capacity exceeding 90 million tests, our business footprint covers the entire domestic market and extends across Europe, North America, Middle East and Asia.
https://www.amp-futurebio.com/